Yazar "Yilmaz, Ahmet" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Prevalence of toxoplasma, cytomegalovirus and rubella in pregnant women in Erzurum, Turkey
    (2021) Yilmaz, Ahmet; Ucar, Mahmut
    Aim: In this study, the seroprevalence of IgM- and IgG- type antibodies against Toxoplasma, Cytomegalovirus (CMV) and Rubella virus was investigated in pregnant women with routine controls performed by family physicians in the city center of Erzurum in a two-year period. It was aimed to compare the obtained data with other studies conducted in our country and in the world. Materials and Methods: The specific results of IgM and IgG serology of Toxoplasma, CMV and rubella of 6798 pregnant women performed by family physicians in the city center of Erzurum between 01.01.2018 and 31.12.2019 were investigated and evaluated according to different age groups in this retrospective cross-sectional study. The serum samples were studied using the Architect i2000 systems with the Chemiluminescent Microparticle Immunoassay (CMIA) method in Erzurum Public Health Microbiology Laboratory. Results: The data of 6798 people between the ages of 15-50 were reached in our study. Toxoplasma, Rubella and CMV- (n = 6586) specific IgM antibody seropositivity rates were found as 0.5%, 0.3% and 0.6%, respectively, while Toxoplasma-, Rubella- and CMV- specific IgG antibody seropositivity rates were found as 20.9%, 88.3% and 99.2%, respectively. Toxoplasma IgG seropositivity rates were determined to increase in parallel with increasing age. Rubella IgG seropositivity rates were decreasing in the 15-24, 25-34 and 35-49 age groups, respectively. The lowest Toxoplasma IgM and CMV IgM seropositivity rates were found in the 35-49 age groups. Conclusions: The two-year seroprevalence of Toxoplasma, CMV and Rubella was determined in pregnant women in our region with this study. Although these seroprevalence rates in Erzurum are generally compatible with other studies conducted in our country, Toxoplasma IgM and rubella IgG seropositivity rates were found to be lower compared to the overall incidence of our country.
  • Küçük Resim
    Öğe
    Research of hepatitis a virus antibodies in children 0-18 aged in the province of Erzurum, Turkey
    (2020) Yilmaz, Ahmet; Sahin, Emine Fusun
    Aim: The aim of the study was to compare the anti-HAV IgG and Anti-HAV IgM seropositivity in children aged 0-18 in Erzurum with studies in our country and other countries, and also to evaluate the effect of seasons on hepatitis A infection.Material and Methods: The study was conducted on the serum samples of 5086 patients aged 0-18 years, who were considered to have Hepatitis A or who applied with different complaints as a result of the examination of family physicians in Erzurum between 2015 and 2018. The results of these patients, obtained from Anti-HAV IgM and Anti-HAV IgG analysis by ELISA method in the Public Health Microbiology Laboratory, were evaluated retrospectively. Pearson chi-square test was used to analyze the categorical data such as gender, age and seasonal differences in anti-HAV IgM and Anti-HAV IgG positivity rates and p 0.05 was considered significant.Results: Anti-HAV IgG seropositivity was 69.0% (3510/5086) and Anti-HAV IgM positivity was 0.7% (33/5063). Anti-HAV IgM was positive in 1.1% of girls and 0.1% of boys. Anti-HAV IgG positivity was 89.9%, 83.3%, 62.5% 61.9% and 74.5% in the 0-3 age group, 4-7 age group, 8-11 age group, 12-15 age group and 16-18 age groups, respectively. Anti-HAV IgM positivity was 0, 0.2%, 0.2%, 1.0%, 0.9% in the 0-3 age group, 4-7 age group, 8-11 age group, 12-15 age group and 16-18 age groups, respectively. The highest anti-HAV IgM positivity was found in November (1.7%).Conclusion: Total anti-HAV IgG seropositivity rate in our province showed many similarities with studies in Turkey and developing countries. The prevalence of anti-HAV IgM was the highest in November.
  • Küçük Resim Yok
    Öğe
    Turkish Real-Life Atrial Fibrillation in Clinical Practice: 2-Year Clinical Outcomes of the TRAFFIC Study
    (Kare Publ, 2026) Karabay, Can; Astarcioglu, Mehmet; Agca, Fahriye; Yilmaz, Ahmet; Akture, Gulsah; Aslan, Ahmet; Ozkalayci, Flora
    Background: Atrial fibrillation (AF) is a major public health issue associated with thromboembolism and mortality. Real-world data from Tü rkiye are limited despite expanding use of non-vitamin K antagonist oral anticoagulants (NOACs). The Turkish Real Life Atrial Fibrillation in Clinical Practice (TRAFFIC) study aimed to characterize the demographic features, risk profiles, treatment patterns, and 2-year clinical outcomes of patients with non-valvular AF (NVAF) in Tü rkiye. Methods: TRAFFIC was a national, prospective, multicenter, observational registry enrolling 1659 NVAF patients from 36 centers with 6-monthly follow-up for 24 months. Baseline data included demographics, comorbidities, CHA2DS2-VASc, HAS-BLED, AF subtype, European Heart Rhythm Association (EHRA) score, and antithrombotictherapy. Outcomes were ischemic stroke/systemic embolism (SE), major bleeding, and all-cause mortality. Predictors of mortality were evaluated using adjusted Cox regression, and associations of risk scores were explored using univariate Cox models with restricted cubic splines. Results: Median age was 70 years, 48% female, with intermediate CHA2DS2-VASc (most 2-5) and low-to-intermediate HAS-BLED scores (most 0-2). Permanent AF wasthe most common subtype (48%). Antithrombotic therapy largely reflected risk profiles, with NOACs being the dominant treatment (65%). Over 2 years, all-cause mortality was 8.9%, ischemic stroke/SE 2.4%, and major bleeding 1.3%. In adjusted analysis, age, congestive heart failure, and diabetes mellitus were independent predictors of mortality. Both CHA2DS2-VASc and HAS-BLED scores showed threshold effects for mortality and thromboembolic risk but notfor bleeding. Conclusion: TRAFFIC provides contemporary Turkish NVAF data, showing lower event rates than historical cohorts. Outcomes are comparable with international registries; persistent mortality burden highlights the needforAF care beyond anticoagulation.